146 related articles for article (PubMed ID: 37316860)
1. Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition.
Coats JT; Tauro S; Sutherland C
Cell Commun Signal; 2023 Jun; 21(1):131. PubMed ID: 37316860
[TBL] [Abstract][Full Text] [Related]
2. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8
Shaw G; Cavalcante L; Giles FJ; Taylor A
J Hematol Oncol; 2022 Sep; 15(1):134. PubMed ID: 36104795
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Carneiro BA; Cavalcante L; Mahalingam D; Saeed A; Safran H; Ma WW; Coveler AL; Powell S; Bastos B; Davis E; Sahai V; Mikrut W; Longstreth J; Smith S; Weisskittel T; Li H; Borden BA; Harvey RD; Sahebjam S; Cervantes A; Koukol A; Mazar AP; Steeghs N; Kurzrock R; Giles FJ; Munster P
Clin Cancer Res; 2024 Feb; 30(3):522-531. PubMed ID: 37982822
[TBL] [Abstract][Full Text] [Related]
4. Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain.
Soutar MP; Kim WY; Williamson R; Peggie M; Hastie CJ; McLauchlan H; Snider WD; Gordon-Weeks PR; Sutherland C
J Neurochem; 2010 Nov; 115(4):974-83. PubMed ID: 20831597
[TBL] [Abstract][Full Text] [Related]
5. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.
Wu X; Stenson M; Abeykoon J; Nowakowski K; Zhang L; Lawson J; Wellik L; Li Y; Krull J; Wenzl K; Novak AJ; Ansell SM; Bishop GA; Billadeau DD; Peng KW; Giles F; Schmitt DM; Witzig TE
Blood; 2019 Jul; 134(4):363-373. PubMed ID: 31101621
[TBL] [Abstract][Full Text] [Related]
6. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Atkinson JM; Rank KB; Zeng Y; Capen A; Yadav V; Manro JR; Engler TA; Chedid M
PLoS One; 2015; 10(4):e0125028. PubMed ID: 25915038
[TBL] [Abstract][Full Text] [Related]
7. A lentivirus-mediated genetic screen identifies dihydrofolate reductase (DHFR) as a modulator of beta-catenin/GSK3 signaling.
Klinghoffer RA; Frazier J; Annis J; Berndt JD; Roberts BS; Arthur WT; Lacson R; Zhang XD; Ferrer M; Moon RT; Cleary MA
PLoS One; 2009 Sep; 4(9):e6892. PubMed ID: 19727391
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-hodgkin lymphoma cells.
Saba NS; Levy LS
J Investig Med; 2012 Jan; 60(1):29-38. PubMed ID: 21997316
[TBL] [Abstract][Full Text] [Related]
9. FNC, a novel nucleoside analogue, blocks invasion of aggressive non-Hodgkin lymphoma cell lines via inhibition of the Wnt/β-catenin signaling pathway.
Zhang Y; Wang CP; Ding XX; Wang N; Ma F; Jiang JH; Wang QD; Chang JB
Asian Pac J Cancer Prev; 2014; 15(16):6829-35. PubMed ID: 25169533
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels.
Yang K; Guo Y; Stacey WC; Harwalkar J; Fretthold J; Hitomi M; Stacey DW
BMC Cell Biol; 2006 Aug; 7():33. PubMed ID: 16942622
[TBL] [Abstract][Full Text] [Related]
11. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
12. GSK3 inhibitors stabilize Wee1 and reduce cerebellar granule cell progenitor proliferation.
Penas C; Mishra JK; Wood SD; Schürer SC; Roush WR; Ayad NG
Cell Cycle; 2015; 14(3):417-24. PubMed ID: 25616418
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis.
Spokoini R; Kfir-Erenfeld S; Yefenof E; Sionov RV
Mol Endocrinol; 2010 Jun; 24(6):1136-50. PubMed ID: 20371704
[TBL] [Abstract][Full Text] [Related]
14. Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.
Mangangcha IR; Brojen Singh RK; Lebeche D; Ali S
J Biomol Struct Dyn; 2022 Oct; 40(17):7868-7884. PubMed ID: 33769184
[TBL] [Abstract][Full Text] [Related]
15. GSK3 protein positively regulates type I insulin-like growth factor receptor through forkhead transcription factors FOXO1/3/4.
Huo X; Liu S; Shao T; Hua H; Kong Q; Wang J; Luo T; Jiang Y
J Biol Chem; 2014 Sep; 289(36):24759-70. PubMed ID: 25053419
[TBL] [Abstract][Full Text] [Related]
16. The involvement of AMPK/GSK3-beta signals in the control of metastasis and proliferation in hepato-carcinoma cells treated with anthocyanins extracted from Korea wild berry Meoru.
Park SY; Lee YK; Lee WS; Park OJ; Kim YM
BMC Complement Altern Med; 2014 Mar; 14():109. PubMed ID: 24666969
[TBL] [Abstract][Full Text] [Related]
17. Identification and regulation of glycogen synthase kinase-3 during bovine embryo development.
Aparicio IM; Garcia-Herreros M; Fair T; Lonergan P
Reproduction; 2010 Jul; 140(1):83-92. PubMed ID: 20427566
[TBL] [Abstract][Full Text] [Related]
18. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.
Wagner FF; Benajiba L; Campbell AJ; Weïwer M; Sacher JR; Gale JP; Ross L; Puissant A; Alexe G; Conway A; Back M; Pikman Y; Galinsky I; DeAngelo DJ; Stone RM; Kaya T; Shi X; Robers MB; Machleidt T; Wilkinson J; Hermine O; Kung A; Stein AJ; Lakshminarasimhan D; Hemann MT; Scolnick E; Zhang YL; Pan JQ; Stegmaier K; Holson EB
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515000
[TBL] [Abstract][Full Text] [Related]
19. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice.
Singh SP; Tao S; Fields TA; Webb S; Harris RC; Rao R
Dis Model Mech; 2015 Aug; 8(8):931-40. PubMed ID: 26092126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
